Trials / Not Yet Recruiting
Not Yet RecruitingNCT06546436
The Safety and Efficiency of a Single Dose of CARC-101C in Patients With Autoimmune Type 1 Diabetes Mellitus
An Open, Dose-escalation Clinical Study to Evaluation of the Safety and Efficiency of a Single Dose of CARC-101C in Patients With Autoimmune Type 1 Diabetes Mellitus
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School · Academic / Other
- Sex
- All
- Age
- 18 Years – 40 Years
- Healthy volunteers
- Not accepted
Summary
This study investigated the safety, efficiency, pharmacokinetics and pharmacokinetics of CARC-101C in patients with autoimmune type 1 diabetes. A single dose, dose escalation, open study design was used.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CARC-101C | Subjects enrolled in the project will received a one-dose injection of CARC-101C |
Timeline
- Start date
- 2024-08-15
- Primary completion
- 2025-11-15
- Completion
- 2027-05-31
- First posted
- 2024-08-09
- Last updated
- 2024-08-09
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06546436. Inclusion in this directory is not an endorsement.